Objective To compare the efficacy of nystatin suspension and fluconazole in the treatment of oropharyngeal candidosis.Methods 40 patients were randomly assigned to nystatin suspension group or fluconazole group.Patients treated with nystatin suspension (n =20) were instructed to use 30ml of nystatin suspension for rinsing for 5 min,3 times daily.Patients treated with fluconazole(n =20) received capsules(150mg) each day.The clinical effect was assessed after treatment for 3 days.The recurrence was assessed 1 week after drug withdrawal.Results The effective rate in the nystatin suspension group and fluconazole group was 80.0％,85.0％,the recurrence rate in two groups was 18.8％,11.8％,respectively.There were no significant differences (all P ＞ 0.05).Conclusion Nystatin suspension is a good therapeutic alternative in the treatment of oropharyngeal candidosis.

OBJECTIVE To investigate the infection status and drug resistance of Mycoplasma strains isolated from genitourinary tract. METHODS The IST kit produced by Bio-Merieux was used to culture the Mycoplasma strains and to do drug susceptibility test. RESULTS The Mycoplasma infection ratio was 41.0%,with Ureaplasma urealyticum(Uu) 71.9%,Mycoplasma hominis(Mh) 2.3%,and mixed infection 25.8%,respectively.The drug susceptibility test showed that drug resistance ratios were as follows: to erythromycin 58.7%,ciprofloxacin 50.0%,ofloxacin 41.3%,pristinamycin 3.3%,josamycin 5.4% and doxycycline 7.6%. CONCLUSIONS Mycoplasma infection in genitourinary tract is mainly due to Uu infection.We should rationally choose and use antibiotics according to the drug susceptibility,and josamycin is very effective.

Objective To analyze the clinical features of tsutsugamushi disease.Methods 113 cases of tsutsugamushi disease from 1991-2005 were reviewed.Results The symptoms of fever,eschar or ulcer,tetter and lymph node tu- mescence accounted for 100%,80.5% (91/113),6.2% (7/113) and 75.2% (85/113) respectively.Liver damage and pulmonary damage were observed in 75.2% (85/113) and 47.8% (54/113) cases.78.8% (89/113) cases were masculine in OX_K check.Conclusion Tsutsugamushi diseases showed complicated and multiple clinical manifestations and more attention should be paid to for avoiding misdiagnosis.

OBJECTIVE: To evaluate the application of flaps or musculocutaneous flaps in repairing cervical postradiation ulcer (cpu) at nasopharyngeal carcinoma. METHOD: Deltopectoral flaps and pectoralis major flaps were applied to repair cervical radiation ulceration with different size and depth in 19 cases. RESULT: Twelve cases repaired with deltopectoral flaps and 7 cases repaired with pectoralis major flaps, impaired wound healing happened at distal end of one deltopectoral flap, and the wound was healing hy second intention after debridement and dressing change. All the other deltopectoral flaps and pectoralis major flaps stayed alive. Flaps stayed alive without the recurrence of ulcer after the long-term follow-up for one to ten years. CONCLUSION The effectiveness of cervical radiation ulceration reconstruction by deltopectoral flaps and pectoralis major flaps was proved. The reconstruction could prevent the recurrence of ulcer. Refer to the poor prognosis of chronic radiation ulceration with expectant treatment, precautions do count.
Adult ; Aged ; Carcinoma ; Female ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma ; Nasopharyngeal Neoplasms ; radiotherapy ; Neck ; Radiation Injuries ; etiology ; surgery ; Reconstructive Surgical Procedures ; methods ; Skin Transplantation ; methods ; Surgical Flaps

Objective To evaluate the safety and efficacy of botulinum toxin type A for injection in the treatment of post-stroke upper limb spasticity (dosage was 200 U,or 240 U if combined with thumb spasticity).Methods The study was a multi-center,stratified block randomized,double-blind,placebocontrolled trial.All the qualificd subjects were from 15 clinical centers from September 2014 to February 2016.They were randomized (2∶1) to injections of botulinum toxin type A made in China (200-240 U;n =118) or placebo (n =60) in pivotal phase after informed consent signed.The study was divided into two stages.The pivotal trial phase included a one-week screening,12-week double-blind treatment,followed by an expanded phase which included six-week open-label treatment.The tone of the wrist,finger,thumb flexors was assessed at baseline and at weeks 0,1,4,6,8,12,16 and 18 using Modified Ashworth Scale (MAS),disability in activities of daily living was rated using the Disability Assessment Scale and impaction on pain,muscle tone and deformity was assessed using the Global Assessment Scale.The primary endpoint was the score difference between botulinum toxin type A and placebo groups in the tone of the wrist flexor using MAS at six weeks compared to baseline.Results Muscle tone MAS score in the wrist flexor of botulinum toxin type A and placebo groups at six weeks changed-1.00 (-2.00,-1.00) and 0.00 (-0.50,0.00) respectively from baseline.Botulinum toxin type A was significantly superior to placebo for the primary endpoint (Z =6.618,P ＜ 0.01).The safety measurement showed 10 subjects who received botulinum toxin type A had 13 adverse reactions,with an incidence of 8.47％ (10/118),and three subjects who received placebo had three adverse reactions,with an incidence of 5.00％ (3/60) during the pivotal trial phase.All adverse reactions were mild to moderate,none serious.There was no significant difference in adverse reactions incidence between the botulinum toxin type A and the placebo groups.During the expanded phase three subjects had four adverse reactions and the incidence was 1.95％.All adverse reactions were mild,none serious.Conclusion Botulinum toxin type A was found to be safe and efficacious for the treatment of post-stroke upper limb spasticity.Clinical Trial Registration:China Drug Trials,CTR20131191